Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease

Projektinformationen

IMMOVA

ID Finanzhilfevereinbarung: 773570

DOI 10.3030/773570

Abgeschlossenes Projekt

EK-Unterschriftsdatum 12 Mai 2017

Startdatum 1 März 2017

Enddatum 31 August 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ALZINOVA AB
Sweden

Ziel

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain.

AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65+), irreversbly destroys brain cells and affects the patient’s cognitive ability. The exact mechanisms leading to AD are unknown. However, it has been found that the disease is linked to the aggregation and deposition of Aβ1-42 – one of the isoforms of fibrous Aβ peptide - into senile plaques in the brain.

In recent years, significant efforts have been made to attempt targeting the clearance of Aβ1-42 through the administration of Aβ antigens (active immunotherapy) or anti-Aβ anti-bodies (passive immunotherapy). However, the development has been fraught with difficulties. Aβ1-42 oligomers are inherently unstable and heterogeneous. This precludes the development of efficient therapies.

Alzinova owns the AβCC peptide™ technology which allows for the development of a vaccine that specifically targets the endogenous substance that causes disease – a feat made possible by the unprecedented capability to stabilise the antigen.
The product will be ready to enter the clinical trial in humans by the end of 2017. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation (to be included in the Phase 2 project). The strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch.

Fighting AD is an EU-wide challenge as it affects 7.3 million people within the EU-27 countries. The effects of AD are devastating not only for the patients, but also for their families. ALZ-101 delivers in this context a strong EU-added value by its potential to stop the progression of AD.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• medical and health sciences › clinical medicine › psychiatry
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• medical and health sciences › basic medicine › immunology › immunotherapy

Programm/Programme

• H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ALZINOVA AB

• Netto-EU-Beitrag: € 50 000,00
• Adresse: ERIK DAHLBERGSGATAN 11 A ; 411 26 GOTEBORG ; Schweden
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Södra Sverige › Västsverige › Västra Götalands län
• Region: Södra Sverige › Västsverige › Västra Götalands län
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00